Management of urticaria: A consensus report

被引：30

作者：

Zuberbier, T

Greaves, MW

Juhlin, L

Merk, H

Stingl, G

Henz, BM

机构：

[1] Humboldt Univ, Charite, Dept Dermatol & Allergy, D-10117 Berlin, Germany

[2] St Thomas Hosp, St Johns Inst Dermatol, London, England

[3] Univ Uppsala Hosp, Dept Dermatol, S-75185 Uppsala, Sweden

[4] Univ Rheinland Westfalen, Dept Dermatol, Aachen, Germany

[5] Gen Hosp Vienna, Dept Dermatol, Vienna, Austria

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS | 2001年 / 6卷 / 02期

关键词：

antihistamine; treatment; wheal;

D O I：

10.1046/j.0022-202x.2001.00023.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

This consensus report is the result of a panel discussion during the International Clinically Oriented ESDR Symposium Urticaria 2000. Urticaria has a profound impact on the quality of life and effective treatment is required. The most important are nonsedating H1 antihistamines. They have been proven to be effective in double-blind controlled studies, but concentrations higher than those recommended may be necessary. Due to different urticaria subtypes and the individual variation in the course of the disease and response to treatment, however, alternative therapies may be required. Immunosuppressive drugs like cyclosporine A and corticosteroids should not be used long term due to undesirable side-effects.

引用

页码：128 / 131

页数：4

共 39 条

[1]

BARLOW RJ, 1993, EUR J DERMATOL, V3, P273

[2] UVA rush hardening for the treatment of solar urticaria [J].